+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
All Ages
All Genders
ID05889247

Randomized Study of Circulating Tumor DNA to Guide Treatment Monitoring in Advanced Non-Small Cell Lung Cancer

Led by Zealand University Hospital · Updated on 2026-01-09

350

Participants Needed

5

Research Sites

261 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the use of liquid biopsy monitoring through circulating tumor DNA ctDNA in patients with advanced non-small cell lung cancer NSCLC who are receiving immunotherapy. This study aims to improve treatment monitoring by reducing ineffective treatments and unnecessary side effects, while also exploring the cost-effectiveness of incorporating liquid biopsy into routine care. It is a prospective randomized interventional study involving multiple clinical oncology departments and led by Zealand University Hospital. Participants are assigned to one of two groups one group will have their treatment monitored using longitudinal ctDNA measurements along with Quality of Life assessments, while the other group will receive standard monitoring through regular CT scans and Quality of Life assessments. In the ctDNA group, treatment may be discontinued earlier than the usual two-year immunotherapy duration if a complete molecular response is detected in plasma, potentially shortening treatment periods for some patients. During the study, patients will undergo regular evaluations that include quality of life assessments, monitoring for adverse events, and tracking the number of treatments received until disease progression. The main outcome measured is overall survival over an average follow-up of three years. Secondary outcomes include physician assessments of quality of life, adverse event recording, treatment frequency, and health cost-utility analysis. The total participation time is approximately three years, during which researchers will assess the clinical benefit and economic impact of ctDNA-guided treatment monitoring.

CONDITIONS

Brief Title

Circulating Tumor DNA Guided Treatment Monitoring in Advanced Lung Cancer

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here